About Endocyte (NASDAQ:ECYT)
Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin (EC1456), the Company's second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company's non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:ECYT
- CUSIP: 29269A10
- Web: www.endocyte.com
- Market Cap: $220.96 million
- Outstanding Shares: 42,575,000
- 50 Day Moving Avg: $2.94
- 200 Day Moving Avg: $2.11
- 52 Week Range: $1.17 - $6.55
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.11
- P/E Growth: 0.00
- Annual Revenue: $70,000.00
- Price / Sales: 3,156.63
- Book Value: $2.72 per share
- Price / Book: 1.91
- EBITDA: ($40,600,000.00)
- Net Margins: -61,437.14%
- Return on Equity: -32.68%
- Return on Assets: -31.29%
- Current Ratio: 22.81%
- Quick Ratio: 22.81%
- Average Volume: 2.98 million shs.
- Beta: 1.62
- Short Ratio: 2.55
Frequently Asked Questions for Endocyte (NASDAQ:ECYT)
What is Endocyte's stock symbol?
Endocyte trades on the NASDAQ under the ticker symbol "ECYT."
How were Endocyte's earnings last quarter?
Endocyte, Inc. (NASDAQ:ECYT) announced its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.03. The firm had revenue of $0.01 million for the quarter. Endocyte had a negative net margin of 61,437.14% and a negative return on equity of 32.68%. During the same period in the prior year, the company posted ($0.25) EPS. View Endocyte's Earnings History.
Where is Endocyte's stock going? Where will Endocyte's stock price be in 2017?
3 brokers have issued twelve-month target prices for Endocyte's stock. Their predictions range from $7.00 to $7.00. On average, they anticipate Endocyte's stock price to reach $7.00 in the next twelve months. View Analyst Ratings for Endocyte.
What are analysts saying about Endocyte stock?
Here are some recent quotes from research analysts about Endocyte stock:
- 1. According to Zacks Investment Research, "Endocyte reported wider than expected loss in second-quarter 2017. During the quarter, the company stopped enrollment in the phase Ib study evaluating EC1456 for lung cancer as well as stop enrollment of taxane-naive metastatic castration-resistant prostate cancer patients for EC1169. The company now plans to focus on its most promising programs like CAR T-cell small-molecule drug conjugates (SMDC) adaptor platform, and its pipeline candidate EC2629. However, with no approved product in its portfolio at the moment, Endocyte has to depend heavily on its partners for top-line growth. Moreover, shares of the company have underperformed the industry year to date." (8/14/2017)
- 2. Cowen and Company analysts commented, "Today a late breaking abstract was presented at the AACR conference with pre-." (4/5/2017)
Who are some of Endocyte's key competitors?
Some companies that are related to Endocyte include Seres Therapeutics (MCRB), Mersana Therapeutics (MRSN), Corbus Pharmaceuticals Holdings (CRBP), Kura Oncology (KURA), BioCryst Pharmaceuticals (BCRX), AVEO Pharmaceuticals (AVEO), NantKwest (NK), CymaBay Therapeutics (CBAY), Urogen Pharma (URGN), Bellicum Pharmaceuticals (BLCM), RA PHARMCTL INC (RARX), GlycoMimetics (GLYC), BioSpecifics Technologies Corp (BSTC), Merus N.V. (MRUS), Geron Corporation (GERN), Edge Therapeutics (EDGE), Minerva Neurosciences (NERV) and ObsEva SA (OBSV).
Who are Endocyte's key executives?
Endocyte's management team includes the folowing people:
- John C. Aplin Ph.D., Independent Chairman of the Board
- Michael A. Sherman, President, Chief Executive Officer, Director
- Michael T. Andriole, Chief Financial Officer
- Philip S. Low Ph.D., Chief Science Officer, Director
- Michael A. Brinkley, Vice President - Quality
- Christopher P. Leamon Ph.D., Vice President - Research
- P. David Mozley M.D., Vice President - Imaging
- Katherine K. Parker, Vice President of Human Resources
- Beth A. Taylor, Corporate Controller
- Cooper Lesley Russell, Director
Who owns Endocyte stock?
Endocyte's stock is owned by a variety of of retail and institutional investors. Top institutional investors include
CAMBRIDGE ISOTOPE LABORATORIES, INC.
(7.10%). Company insiders that own Endocyte stock include Christopher P Leamon, Fred A Middleton and Philip S Low. View Institutional Ownership Trends for Endocyte.
How do I buy Endocyte stock?
Shares of Endocyte can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Endocyte's stock price today?
MarketBeat Community Rating for Endocyte (NASDAQ ECYT)MarketBeat's community ratings are surveys of what our community members think about Endocyte and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Endocyte stock can currently be purchased for approximately $5.19.
Consensus Ratings for Endocyte (NASDAQ:ECYT) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 2 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.67)|
|Consensus Price Target: ||$7.00 (34.87% upside)|Consensus Price Target History for Endocyte (NASDAQ:ECYT)
Analysts' Ratings History for Endocyte (NASDAQ:ECYT)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/2/2017||Cowen and Company||Reiterated Rating||Hold||High|
|10/3/2017||Wedbush||Upgrade||Neutral -> Outperform||$2.00 -> $7.00||High|
|11/11/2016||Credit Suisse Group||Reiterated Rating||Buy||$7.00||N/A|
|11/4/2015||Royal Bank Of Canada||Lower Price Target||Outperform||$13.00 -> $10.00||N/A|
Earnings History for Endocyte (NASDAQ:ECYT)Earnings History by Quarter for Endocyte (NASDAQ ECYT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/8/2017||Q2 2017||($0.25)||($0.28)||$0.01 million||View||Listen|
|5/10/2017||Q1 2017||($0.28)||($0.27)||$0.01 million||View||N/A|
|3/10/2017||Q4 2016||($0.25)||($0.26)||$0.01 million||View||N/A|
|3/2/2015||Q414||($0.24)||($0.19)||$2.55 million||$12.00 million||View||N/A|
|11/5/2014||Q314||($0.21)||($0.14)||$5.10 million||$3.90 million||View||N/A|
|7/29/2014||Q214||$0.11||$0.52||$26.62 million||$49.17 million||View||N/A|
|5/2/2014||Q114||($0.15)||($0.09)||$15.07 million||$17.30 million||View||N/A|
|2/24/2014||Q413||($0.14)||($0.08)||$15.90 million||$17.30 million||View||N/A|
|5/2/2013||Q1 2013||($0.06)||($0.11)||$14.24 million||$14.50 million||View||N/A|
|4/15/2013||Q413||($0.10)||$8.50 million||$13.60 million||View||N/A|
Earnings Estimates for Endocyte (NASDAQ:ECYT)
2017 EPS Consensus Estimate: ($1.33)
2018 EPS Consensus Estimate: ($0.90)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Endocyte (NASDAQ:ECYT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Endocyte (NASDAQ:ECYT)
Insider Ownership Percentage: 14.86%Insider Trades by Quarter for Endocyte (NASDAQ:ECYT)
Institutional Ownership Percentage: 28.83%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/30/2016||Christopher P. Leamon||VP||Sell||23,244||$2.55||$59,272.20|| |
|5/10/2016||Philip S Low||Insider||Buy||11,375||$3.52||$40,040.00|| |
|1/19/2016||Fred A. Middleton||Director||Buy||10,000||$2.79||$27,900.00|| |
|1/15/2016||Fred A. Middleton||Director||Buy||20,000||$2.80||$56,000.00|| |
|4/9/2014||Allen Ritter||VP||Sell||1,000||$21.16||$21,160.00|| |
|3/21/2014||Allen Ritter||VP||Sell||8,000||$33.11||$264,880.00|| |
|2/14/2014||Philip Low||Insider||Sell||6,000||$15.00||$90,000.00|| |
|12/2/2013||P Ron Ellis||CEO||Sell||3,000||$12.00||$36,000.00|| |
|9/16/2013||Allen Ritter||VP||Sell||2,000||$17.06||$34,120.00|| |
|9/12/2013||David Meek||Insider||Sell||10,000||$15.50||$155,000.00|| |
|9/3/2013||P Ron Ellis||CEO||Sell||3,000||$14.54||$43,620.00|| |
|8/30/2013||Allen Ritter||VP||Sell||6,000||$14.36||$86,160.00|| |
|8/6/2013||Chandra Lovejoy||VP||Sell||7,000||$17.29||$121,030.00|| |
|8/1/2013||P Ron Ellis||CEO||Sell||3,000||$18.12||$54,360.00|| |
|7/15/2013||P Ron Ellis||CEO||Sell||3,000||$17.01||$51,030.00|| |
|5/28/2013||Ann Hanham||Director||Sell||9,900||$14.10||$139,590.00|| |
|5/22/2013||Ann Hanham||Director||Sell||40,000||$14.38||$575,200.00|| |
|5/17/2013||Ann Hanham||Director||Sell||37,200||$14.41||$536,052.00|| |
|5/17/2013||Binh Nguyen||VP||Sell||17,300||$14.42||$249,466.00|| |
|5/15/2013||Ann Hanham||Director||Sell||40,200||$14.69||$590,538.00|| |
|5/14/2013||Christopher P Leamon||VP||Sell||5,000||$14.70||$73,500.00|| |
|2/25/2013||Chandra D Lovejoy||VP||Sell||2,102||$9.70||$20,389.40|| |
|12/26/2012||Chandra D Lovejoy||VP||Sell||2,209||$9.05||$19,991.45|| |
|11/26/2012||Chandra D Lovejoy||VP||Sell||2,209||$8.72||$19,262.48|| |
Headline Trends for Endocyte (NASDAQ:ECYT)
Latest Headlines for Endocyte (NASDAQ:ECYT)
Loading headlines, please wait.
Endocyte (ECYT) Chart for Sunday, October, 22, 2017